IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
Clinical trial NCT07402070 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07402070
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-04
- Primary completion
- 2026-12-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.